Human Chorionic Gonadotropin
Approved fertility/endocrine drug with established medical uses
Brief Overview: hCG is an LH-like hormone used medically in fertility and endocrine care. In men, it can stimulate Leydig cells to produce testosterone; In women, it can trigger ovulation in supervised protocols. Evidence lens: Unlike many entries, hCG has legitimate approved medical uses. The danger is not lack of biology; The danger is unsupervised endocrine manipulation, fertility complications, gynecomastia, testicular axis suppression/rebound issues, and pregnancy-related risks. How to read this: if you're new, understand that blood levels reaching steady state in days is not the same as fertility response. Once you're past the basics, monitor the hypothalamic-pituitary-gonadal axis, estradiol, semen parameters where relevant, and pregnancy/ovarian risks under clinician oversight.
- hCG is a naturally occurring glycoprotein hormone produced by the syncytiotrophoblast cells of the placenta during pregnancy.
- In a research and clinical context, it is derived from either the urine of pregnant women or manufactured via recombinant DNA technology.
- It is classified as a gonadotropin and acts as a biological “mimic” of Luteinizing Hormone (LH).
- hCG is a glycoprotein hormone with LH-like activity, not a small synthetic peptide. Its relevance is fertility, testicular steroidogenesis, and specific endocrine indications.
hCG shares an identical alpha subunit with Luteinizing Hormone (LH) and a very similar beta subunit, allowing it to bind to the same receptors:
- Testicular Activation: It binds to the LH/hCG receptors on the Leydig cells of the testes. This triggers the conversion of cholesterol into pregnenolone, ultimately stimulating the endogenous production of testosterone.
- Ovarian Stimulation: In females, it triggers ovulation and supports the corpus luteum for progesterone production.
- Bypassing the Pituitary: hCG acts directly on the gonads. It provides a signal for hormone production even when the pituitary gland is suppressed (e.g., during HRT, TRT, or anabolic use).
- Intratesticular Testosterone (ITT): Crucially, hCG maintains high levels of ITT, which is essential for spermatogenesis (sperm production) and preventing testicular atrophy.
- hCG activates LH receptors, stimulating Leydig-cell testosterone production and supporting ovarian processes depending on sex and context. It can raise testosterone and estradiol downstream. The mechanism here is a plausibility map, not proof of a clinical outcome.
- HPTA Maintenance: Research in 2025 has solidified hCG as the “gold standard” for preventing the “shutdown” of the Hypothalamic-Pituitary-Testicular Axis (HPTA).
- Neurosteroid Production: Emerging studies show that hCG stimulation of the Leydig cells also increases neurosteroids like pregnenolone and DHEA, which are often depleted during hormonal suppression and contribute to “brain fog.” Metabolic Impact: While the “hCG Diet” (500 calories + hCG) has been largely debunked as ineffective for fat loss specifically, recent 2026 data suggest hCG helps maintain lean mass and metabolic rate during extreme caloric deficits.
- Fertility Recovery: 2025 clinical meta-analyses confirm that lowdose, frequent hCG administration is significantly more effective at maintaining fertility than high-dose, infrequent “bolus” injections.
- hCG has established clinical use in fertility/endocrinology, but weight-loss or casual testosterone-stack claims are separate from evidence-based fertility/endocrinology claims. The discredited hCG diet concept is not evidence-based weight management. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: HPTA Maintenance (On-Cycle) [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC) or Intramuscular (IM); Dose: 250 IU – 500 IU; Frequency: 2 to 3 times weekly; Duration: Length of suppressive cycle; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: Post-Cycle Therapy (PCT) [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC) or Intramuscular (IM); Dose: 1,000 IU – 2,500 IU; Frequency: Every other day (for 2 weeks); Duration: 10–14 days; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 3: Pregnyl FDA-label male hypogonadotropic hypogonadism regimen 1 [FDA/Approved/Label]; Route: Intramuscular injection; Dose: 500 USP units – 1,000 USP units; Frequency: 3 times per week for 3 weeks, then same dose 2 times per week for 3 weeks; Duration: 6-week labeled regimen; Status: Yes - FDA-approved label/product protocol for labeled indication only.
- Protocol 4: Pregnyl FDA-label male hypogonadotropic hypogonadism regimen 2 [FDA/Approved/Label]; Route: Intramuscular injection; Dose: 4,000 USP units, then 2,000 USP units; Frequency: 4,000 USP units 3 times per week for 6–9 months; Then 2,000 USP units 3 times per week for 3 months; Duration: 9–12 months labeled regimen; Status: Yes - FDA-approved label/product protocol for labeled indication only.
- Protocol 5: Pregnyl FDA-label ovulation trigger context [FDA/Approved/Label]; Route: Intramuscular injection; Dose: 5,000 USP units – 10,000 USP units; Frequency: One dose; Timing: One day following last dose of menotropins, per labeled ovulation-induction context; Status: Yes - FDA-approved label/product protocol for labeled indication only.
- Doses are in IU and are goal-specific. Fertility induction, hypogonadotropic hypogonadism, and post-anabolic recovery claims are not interchangeable protocols. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
hCG has a notably long biological half-life (~36 hours) compared to native LH, allowing for less frequent dosing. Subcutaneous and intramuscular routes both yield similar bioavailability for clinical use. Peak serum levels occur 6 to 12 hours post-injection, with sustained Leydig cell stimulation for 48 to 72 hours after a single dose.
- Time until steady state: about 6-8 days.
- Half-life basis: Terminal half-life about 29-37 hours depending preparation/source. The LH-like endocrine effect can persist for days after a dose; Steady-state timing does not equal time to spermatogenesis or fertility response.
- Beginner translation: This estimate uses the standard four-to-five-half-life convention. It describes when plasma exposure would be expected to approach a plateau during repeated dosing, not when the desired outcome is complete.
- hCG has longer biological action than native LH. Effects on testosterone/estradiol may persist beyond the injection window, so weekly totals and lab timing matter. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
hMG (Human Menopausal Gonadotropin): Often stacked with hCG for infertility cases. While hCG mimics LH (testosterone), hMG mimics FSH (sperm maturation).
- TRT (Testosterone Replacement): Used as an “ancillary” to maintain testicular size and fertility while on TRT.
- Enclomiphene: Used after an hCG “kickstart” to signal the pituitary to resume its own LH production.
- Common stacks include hMG/FSH for spermatogenesis or testosterone-management contexts. Combining with testosterone, SERMs, aromatase inhibitors, or gonadotropins requires endocrine logic and labs. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Estrogen Spikes: Because hCG is a potent stimulator of the aromatase enzyme in the testes, it often causes a significant rise in Estradiol (E2).
- Gynaecomastia: High doses can cause nipple sensitivity or breast tissue growth due to the aforementioned estrogen rise.
- Acne and Hair Loss: Resulting from the rapid increase in testosterone and subsequent DHT conversion.
- Leydig Cell Desensitization: Chronic high-dose use may eventually make the testes less responsive to LH/hCG signals.
- Risks include gynecomastia, acne, mood changes, water retention, fertility-protocol complications, and estrogen excess. In women, ovarian hyperstimulation and multiple gestation are major concerns. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- Total & Free Testosterone: To ensure the gonads are responding to the signal.
- Estradiol (Sensitive): Critical to monitor, as hCG-driven estrogen spikes often require management with an Aromatase Inhibitor (AI).
- Hematocrit: Like testosterone, hCG can stimulate red blood cell production, though usually to a lesser degree.
- Track testosterone, estradiol, LH/FSH suppression context, semen analysis, testicular volume if relevant, pregnancy/ovarian monitoring in women, and symptoms of estrogen excess. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- FDA Status: FDA-approved for the treatment of hypogonadotropic hypogonadism and ovulation induction. However, in 2020, the FDA reclassified hCG as a biological product, which limited its production by many traditional compounding pharmacies.
- WADA: Strictly Banned for males at all times (as it increases testosterone production). It is not banned for females unless used as a masking agent.
- Availability: Requires a prescription. In 2026, many researchers source it through “Fertility Clinics” or specialized HRT providers.
- hCG has approved medical uses, but some marketed weight-loss uses and research-market products are not equivalent to approved prescribing. Product source matters. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.